Cargando…

miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome

In primary Sjögren’s syndrome (pSS) the exocrine glands become infiltrated with lymphocytes instigating severe damage to the salivary and lacrimal glands causing dry eyes and dry mouth. Previous investigations have suggested that dysregulated localized and systemic inflammation contributes to the de...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilson, Qistina, Smith, Siobhan, Jefferies, Caroline A., Ní Gabhann-Dromgoole, Joan, Murphy, Conor C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198540/
https://www.ncbi.nlm.nih.gov/pubmed/32366870
http://dx.doi.org/10.1038/s41598-020-64422-5
_version_ 1783529007773384704
author Pilson, Qistina
Smith, Siobhan
Jefferies, Caroline A.
Ní Gabhann-Dromgoole, Joan
Murphy, Conor C.
author_facet Pilson, Qistina
Smith, Siobhan
Jefferies, Caroline A.
Ní Gabhann-Dromgoole, Joan
Murphy, Conor C.
author_sort Pilson, Qistina
collection PubMed
description In primary Sjögren’s syndrome (pSS) the exocrine glands become infiltrated with lymphocytes instigating severe damage to the salivary and lacrimal glands causing dry eyes and dry mouth. Previous investigations have suggested that dysregulated localized and systemic inflammation contributes to the development and pathogenesis of pSS. A miR microarray performed in primary human conjunctival epithelial cells (PECs) demonstrated significant differences in miR expression at the ocular surface between pSS patients and healthy controls. MicroRNA-744-5p (miR-744-5p) was identified as being of particular interest, as its top predicted target is Pellino3 (PELI3), a known negative regulator of inflammation. Validation studies confirmed that miR-744-5p expression is significantly increased in PECs from pSS patients, whilst PELI3 was significantly reduced. We validated the miR-744 binding site in the 3’ untranslated region (UTR) of PELI3 and demonstrated that increasing PELI3 levels with a miR-744-5p antagomir in an inflammatory environment resulted in reduced levels of IFN dependent chemokines Rantes (CCL5) and CXCL10. These results reveal a novel role for miR-744-5p in mediating ocular inflammation via Pellino3 expression in pSS patients and suggest that miR-744-5p may be a potential therapeutic target for the management of severe dry eye disease and ocular inflammation in pSS patients.
format Online
Article
Text
id pubmed-7198540
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71985402020-05-08 miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome Pilson, Qistina Smith, Siobhan Jefferies, Caroline A. Ní Gabhann-Dromgoole, Joan Murphy, Conor C. Sci Rep Article In primary Sjögren’s syndrome (pSS) the exocrine glands become infiltrated with lymphocytes instigating severe damage to the salivary and lacrimal glands causing dry eyes and dry mouth. Previous investigations have suggested that dysregulated localized and systemic inflammation contributes to the development and pathogenesis of pSS. A miR microarray performed in primary human conjunctival epithelial cells (PECs) demonstrated significant differences in miR expression at the ocular surface between pSS patients and healthy controls. MicroRNA-744-5p (miR-744-5p) was identified as being of particular interest, as its top predicted target is Pellino3 (PELI3), a known negative regulator of inflammation. Validation studies confirmed that miR-744-5p expression is significantly increased in PECs from pSS patients, whilst PELI3 was significantly reduced. We validated the miR-744 binding site in the 3’ untranslated region (UTR) of PELI3 and demonstrated that increasing PELI3 levels with a miR-744-5p antagomir in an inflammatory environment resulted in reduced levels of IFN dependent chemokines Rantes (CCL5) and CXCL10. These results reveal a novel role for miR-744-5p in mediating ocular inflammation via Pellino3 expression in pSS patients and suggest that miR-744-5p may be a potential therapeutic target for the management of severe dry eye disease and ocular inflammation in pSS patients. Nature Publishing Group UK 2020-05-04 /pmc/articles/PMC7198540/ /pubmed/32366870 http://dx.doi.org/10.1038/s41598-020-64422-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Pilson, Qistina
Smith, Siobhan
Jefferies, Caroline A.
Ní Gabhann-Dromgoole, Joan
Murphy, Conor C.
miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome
title miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome
title_full miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome
title_fullStr miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome
title_full_unstemmed miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome
title_short miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome
title_sort mir-744-5p contributes to ocular inflammation in patients with primary sjogrens syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198540/
https://www.ncbi.nlm.nih.gov/pubmed/32366870
http://dx.doi.org/10.1038/s41598-020-64422-5
work_keys_str_mv AT pilsonqistina mir7445pcontributestoocularinflammationinpatientswithprimarysjogrenssyndrome
AT smithsiobhan mir7445pcontributestoocularinflammationinpatientswithprimarysjogrenssyndrome
AT jefferiescarolinea mir7445pcontributestoocularinflammationinpatientswithprimarysjogrenssyndrome
AT nigabhanndromgoolejoan mir7445pcontributestoocularinflammationinpatientswithprimarysjogrenssyndrome
AT murphyconorc mir7445pcontributestoocularinflammationinpatientswithprimarysjogrenssyndrome